Cosmos Health Launches Subscription Model

About this update from Cosmos Health Inc.

CHICAGO, July 10, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has launched a subscription-based purchasing model for its proprietary consumer health brands. The model is currently live with NOOR Collagen in the United States, with encouraging early results that include a repeat purchase rate above 60% and margins in excess of 50%. NOOR Collagen is a proprietary product formulated with premium marine collagen tripeptide, currently available in capsule form, with a formula designed to support skin and joint health. The Company plans to extend the subscription model to a broader range of its consumer health products across its brands and markets globally, with further initiatives already underway. Cosmos Health expects the model to offer several benefits: The Company expects to provide additional details, including sales, repeat purchase and retention rates, and margins, as the model matures. Greg Siokas, CEO of Cosmos Health, stated: "A subscription model is a natural next step in deepening our relationship with consumers and building recurring revenue across our brands. The early response to our NOOR Collagen subscription in the United States has been encouraging, and by pairing our science-driven products with personalized guidance, we believe we can drive stronger loyalty, greater lifetime value, and more predictable revenue as we grow." About Cosmos Health Inc. Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com , www.skypremiumlife.com , www.cana.gr , www.zipdoctor.co , www.cloudscreen.gr , as well as LinkedIn and X .

View stock analysis, news, and events for Cosmos Health Inc.